SCHEMBL12367461

SCHEMBL12367461

CCCn1c(Cc2ccc(OC(F)(F)F)cc2)cc2cc(NC(=N)c3cccs3)ccc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
LMNA P02545 2/20 0.38
MAPK1 P28482 1/20 0.38
RAB9A P51151 5/20 0.38
NPC1 O15118 4/20 0.38
ATM Q13315 1/20 0.35
POLB P06746 1/20 0.35
ADORA2A P29274 1/20 0.35
ADORA2B P29275 1/20 0.35
ITK Q08881 1/20 0.34
KCNA5 P22460 2/20 0.34
MCHR1 Q99705 2/20 0.34
CNR2 P34972 1/20 0.34
NOS3 P29474 1/20 0.34
NOS1 P29475 1/20 0.34
ALDH1A1 P00352 2/20 0.33
GAA P10253 1/20 0.33
IDH1 O75874 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2262327 0.91 NOS3 (0.41) SMN1; SMN2MEN1KMT2ALMNAMAPK1
SCHEMBL2262457 0.87 NOS3 (0.51) SMN1; SMN2LMNAMCHR1NOS3NOS1
SCHEMBL15178523 0.85 NOS3 (0.36) SMN1; SMN2MEN1KMT2ALMNAMAPK1
SCHEMBL12390571 0.78 NOS3 (0.40) SMN1; SMN2MEN1KMT2ARAB9ANPC1
SCHEMBL14404689 0.77 NOS3 (0.52) NOS3NOS1
SCHEMBL12391672 0.75 NOS3 (0.54) NOS3NOS1
SCHEMBL2262112 0.74 NOS3 (0.62) ITKNOS3NOS1
SCHEMBL12367463 0.74 MBOAT4 (0.40) SMN1; SMN2MEN1KMT2ALMNAMAPK1
SCHEMBL2262329 0.72 NOS1 (0.60) NOS3NOS1
SCHEMBL12367457 0.70 CNR2 (0.42) MEN1KMT2ACNR2MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989447-B2 1,5 and 3,6-substituted indole compounds having NOS inhibitory activity NEURAXON, INC. (CA) 2011-08-02 US disclosed
US-20070254940-A1 1,5 And 3,6- substituted indole compounds having NOS inhibitory activity NEURAXON, INC. (CA) 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254940-A1 1,5 And 3,6- substituted indole compounds having NOS inhibitory activity NOS1, NOS3, NOS2 SMN1; SMN2 1363/4885MEN1 2669/4885KMT2A 3297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.